Lightcast Appoints Sarah Taylor, PhD, as Vice President of Science to Advance Envisia Single-Cell Analysis Platform
Lightcast, a life science tools company focused on functional single-cell analysis, has appointed Sarah Taylor, PhD, as Vice President of Science, effective immediately. Taylor joins the company from 10x Genomics, bringing more than a decade of experience in life science technology development, product innovation, applications development and commercialization.
Her appointment strengthens Lightcast’s scientific and commercial leadership as the company works to advance its Envisia™ single-cell functional analysis platform and expand the technology’s applications across research and drug discovery. In her new role, Taylor will collaborate with Lightcast’s scientific, engineering and market development teams to support the continued development of the platform, establish strategic relationships and help position the company’s technology for broader commercial adoption.
The leadership appointment comes as functional single-cell analysis continues to attract growing interest across life science research. Researchers are increasingly seeking technologies that can move beyond genomic and transcriptomic measurements to directly characterize what individual cells do and how they interact with their environment.
Lightcast believes its Envisia platform can address this need by capturing functional information directly at the single-cell level.
Taylor Brings Broad Life Science Technology Experience
Taylor brings extensive experience working across scientific research, technology development and commercialization. During her tenure at 10x Genomics, she led cross-functional initiatives involving biology, computational science, engineering and commercial teams.
Her work included helping move technologies and programs from early-stage concepts through development and product launch. She also built an applications organization designed to support customer adoption and facilitate the use of emerging technologies across research workflows.
In addition to her product and applications experience, Taylor led business development activities at 10x Genomics, where she established and managed commercial and strategic partnerships.
This combination of scientific, technical and commercial experience is expected to be particularly relevant to Lightcast as the company works to expand the Envisia platform and identify additional applications for its technology.
Taylor began her industry career at Clontech Laboratories, Inc., which was acquired by Takara Bio USA Inc. in 2005. Her industry background is complemented by academic research experience.
She earned a PhD in cell and molecular biology from University College London and subsequently conducted postdoctoral research at Stanford University.
Her scientific training provides a foundation in cell biology and molecular biology, while her industry experience has focused on translating scientific concepts into technologies and products that can be adopted by researchers.
Strengthening Lightcast’s Scientific and Commercial Leadership
Lightcast CEO Paul Loeffen, PhD, said Taylor’s appointment comes at an important point in the company’s growth.
“We are thrilled to welcome Sarah to the Lightcast team at this pivotal stage in our growth,” Loeffen said.
He highlighted Taylor’s combination of scientific expertise, technology knowledge and commercial leadership, as well as her experience bringing together multidisciplinary teams.
According to Loeffen, Taylor’s ability to connect biology, computation and engineering will be important as Lightcast develops new applications for its Envisia platform. Her experience forming strategic partnerships and translating innovative technologies into scalable products is also expected to support the company’s commercial objectives.
The company is seeking to expand the role of functional single-cell analysis in life science research and establish Envisia as a platform capable of supporting a range of applications.
Taylor’s appointment therefore represents more than an expansion of the company’s scientific team. It adds an executive with experience spanning product development, applications, partnerships and commercialization at a time when Lightcast is seeking to increase the reach and impact of its technology.
Envisia Targets Functional Single-Cell Analysis
The Envisia platform is designed to address a limitation associated with conventional single-cell analysis technologies.
Many existing single-cell approaches rely heavily on genomic or transcriptomic information to infer cellular behavior or function. While these measurements can provide detailed information about the molecular state of individual cells, they do not necessarily capture functional activity directly.
Lightcast’s approach is focused on measuring functional characteristics at the single-cell level.
The Envisia platform is powered by the company’s proprietary light-controlled droplet manipulation technology. The system enables researchers to interrogate tens of thousands of picoliter-scale droplets at high speed while maintaining control and flexibility over experimental workflows.
By working with individual cells encapsulated within droplets, researchers can conduct highly controlled experiments designed to evaluate cellular function.
The technology is intended to provide researchers with direct functional information that can complement genomic and transcriptomic data.
This distinction could be important in areas such as antibody discovery, immunology and oncology, where understanding how individual cells behave and interact can be critical to identifying promising biological candidates.
Applications in Antibody Discovery
One of the areas where Lightcast is applying Envisia is antibody discovery.
Antibody discovery programs often require researchers to identify individual cells producing antibodies with desirable characteristics. Conventional approaches can involve multiple screening and characterization steps, which may make the process time-consuming or limit the amount of functional information available during early discovery.
According to Lightcast, Envisia can support sequential single-cell functional screening assays, enabling researchers to interrogate large numbers of cells and rapidly evaluate functional properties.
The ability to analyze tens of thousands of picoliter-scale droplets could potentially help researchers increase the throughput of functional screening workflows.
By providing more direct functional information, the platform could help researchers identify promising antibody candidates earlier in the discovery process.
Lightcast is also exploring the use of the technology for other applications in which functional measurements at the single-cell level could provide valuable insights.
Exploring Cell-Cell Interactions
Beyond antibody discovery, Envisia is being used to investigate cell-cell interactions.
Cellular interactions play an important role in many biological processes, including immune responses, disease progression and therapeutic activity. However, understanding these interactions at the level of individual cells can be challenging because cellular behavior can vary significantly across a population.
Single-cell functional analysis can provide an opportunity to examine these differences more directly.
Lightcast’s droplet-based approach allows researchers to perform controlled experiments involving individual cells and assess functional responses. This could support studies examining how immune cells interact with target cells or how specific cellular populations influence one another.
Such capabilities may have applications across immunology and oncology, where researchers are increasingly interested in understanding cellular heterogeneity and functional relationships within complex biological systems.
Potential Impact on Immunology and Oncology Research
Immunology and oncology are two additional areas in which functional single-cell analysis could have significant value.
Tumors contain diverse populations of cancer cells and immune cells, each with different molecular and functional characteristics. Understanding these cellular differences can help researchers investigate disease mechanisms and identify potential therapeutic targets.
Similarly, immune responses can involve highly complex interactions among different cell types. Genomic information can reveal which genes are expressed, but direct functional measurements may provide additional insight into how individual cells respond to stimuli or interact with other cells.
Lightcast’s technology is being developed to provide this type of functional information.
The company believes the Envisia platform can complement existing single-cell genomics and transcriptomics technologies by adding direct functional measurements to researchers’ workflows.
Focus on Partnerships and Global Expansion
Taylor’s background in business development and strategic partnerships is expected to support Lightcast’s efforts to expand its capabilities and global reach.
At 10x Genomics, she was involved in establishing and driving commercial and strategic partnerships. This experience could help Lightcast identify opportunities to work with biotechnology companies, pharmaceutical organizations, academic institutions and other life science researchers.
Strategic partnerships can play an important role for emerging life science technology companies by expanding access to new applications, accelerating technology adoption and creating opportunities to integrate platforms into established research workflows.
Taylor’s combination of scientific expertise and commercial experience positions her to contribute to these efforts while continuing to support the development of the Envisia platform.
Taylor Outlines Vision for New Role
Taylor said she sees a significant opportunity for Lightcast to advance single-cell analysis by providing researchers with deeper insight into cellular function.
“Lightcast has a significant opportunity to advance single-cell analysis and address increasingly complex questions about cellular function,” Taylor said.
She added that she was excited to join the company and work with customers, strategic partners and colleagues to accelerate innovation, expand the platform and support the company’s next phase of growth.
Her comments reflect Lightcast’s broader strategy of combining technology development with customer-focused applications and partnerships.
As research questions become increasingly complex, researchers may require technologies capable of integrating different types of biological information. Functional analysis could provide another layer of insight alongside genomic, transcriptomic and other molecular measurements.
Taylor’s appointment marks an important step for Lightcast as the company seeks to expand the commercial and scientific potential of its Envisia single-cell functional analysis platform.
Her more than decade of experience in life science technology development, applications, product commercialization and business development provides the company with expertise across multiple aspects of technology adoption. Her previous work at 10x Genomics, combined with her scientific training in cell and molecular biology, is expected to support Lightcast’s efforts to translate its technology into broader research applications.
Envisia’s light-controlled droplet manipulation technology is designed to enable high-throughput interrogation of tens of thousands of picoliter-scale droplets while supporting controlled, sequential functional assays. The platform is currently being applied to antibody discovery, cell-cell interaction studies and broader research programs in immunology and oncology.
As Lightcast continues to develop the platform, expand partnerships and increase its global presence, Taylor will play a central role in connecting scientific innovation with practical research applications and commercial opportunities.
The company’s focus on functional single-cell analysis reflects a growing effort within life sciences to understand not only the molecular characteristics of individual cells but also their actual behavior and function. By seeking to capture functional information directly, Lightcast aims to provide researchers with additional tools for investigating complex biological systems and accelerating the development of new therapeutics.
About Lightcast
Lightcast aims to unleash new capabilities within the single-cell analysis field by developing a more accessible, scalable, and flexible platform for scientists in basic, translational, and applied research. These capabilities will empower new biological discoveries and accelerate the development of novel drugs, therapies, and biologics. Founded in 2019 and based in Cambridge, UK, Lightcast has invented a technology that uses rays of light to control picoliter-scale droplets for functional analysis of individual cells. For more information, visit www.lightcast.bio.
Lightcast, the Lightcast logo, and Envisia are trademarks of Lightcast Discovery Ltd.